Thiago Carvalho on Nostr: “It is definitely not an easy discussion with our patients when you say you have ...
“It is definitely not an easy discussion with our patients when you say you have evidence for a drug that may be helpful for their care, and yet you know they do not have coverage, whether private or public funding.” This was especially the case for rare tumours where drug approvals or relevant clinical trials were often not available, she said.'
https://www.ft.com/content/4dfc5540-da29-4701-b773-6e02b4c71a1ePublished at
2024-09-08 07:29:02Event JSON
{
"id": "7ffeecbd6e8fe029665b31e2799779c9a9650c1b9c22bf375b05deac42478208",
"pubkey": "376d961fc946cb96839a4d257809dc9e6d237e2d0cc158199b8cc5c5771939a6",
"created_at": 1725780542,
"kind": 1,
"tags": [
[
"proxy",
"https://qoto.org/users/cyrilpedia/statuses/113100753596760076",
"activitypub"
]
],
"content": "“It is definitely not an easy discussion with our patients when you say you have evidence for a drug that may be helpful for their care, and yet you know they do not have coverage, whether private or public funding.” This was especially the case for rare tumours where drug approvals or relevant clinical trials were often not available, she said.'\nhttps://www.ft.com/content/4dfc5540-da29-4701-b773-6e02b4c71a1e",
"sig": "f9ea25613a6bff1db6be2fae2303160312baa61f480ada34b2d4ec836845098750246337ae98248bff57ec69288337d7beaba2370b469d9a373a753686beb11c"
}
